{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T20:42:10Z","timestamp":1793652130422,"version":"4.5.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008052","name":"Fundaci\u00f3n Alfonso Mart\u00edn Escudero","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL142768-01"],"award-info":[{"award-number":["R01 HL142768-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 HL149137-01"],"award-info":[{"award-number":["R01 HL149137-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ymthe.2025.11.015","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T08:38:54Z","timestamp":1763627934000},"page":"1066-1083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A tumor-selective mRNA system enables precision cancer treatment"],"prefix":"10.1016","volume":"34","author":[{"given":"Magdalena M.","family":"\u017bak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimeen","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Utrero-Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wencke","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Mainkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Adjmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann Anu","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashikur","family":"Rahaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Lozano","family":"Ojalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ochando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Haferlach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon E.","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip K.","family":"Swirski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6153-9857","authenticated-orcid":false,"given":"Lior","family":"Zangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2025.11.015_bib1","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.11.015_bib2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"New Engl. J. Med."},{"key":"10.1016\/j.ymthe.2025.11.015_bib3","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","article-title":"Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Karik\u00f3","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.11.015_bib4","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/j.ymthe.2025.11.015_bib5","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/nbt.2682","article-title":"Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction","volume":"31","author":"Zangi","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.11.015_bib6","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/CIRCULATIONAHA.119.041882","article-title":"Altering Sphingolipid Metabolism Attenuates Cell Death and Inflammatory Response After Myocardial Infarction","volume":"141","author":"Hadas","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2025.11.015_bib7","doi-asserted-by":"crossref","first-page":"2004661","DOI":"10.1002\/advs.202004661","article-title":"Therapeutic Delivery of Pip4k2c-Modified mRNA Attenuates Cardiac Hypertrophy and Fibrosis in the Failing Heart","volume":"8","author":"Magadum","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ymthe.2025.11.015_bib8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ymthe.2022.11.017","article-title":"Direct intramyocardial injection of VEGF mRNA in patients undergoing coronary artery bypass grafting","volume":"31","author":"Anttila","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2025.11.015_bib9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature21428","article-title":"Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination","volume":"543","author":"Pardi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.11.015_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.omtn.2019.03.003","article-title":"Characterization of HIV-1 Nucleoside-Modified mRNA Vaccines in Rabbits and Rhesus Macaques","volume":"15","author":"Pardi","year":"2019","journal-title":"Mol. Ther. - Nucleic Acids"},{"key":"10.1016\/j.ymthe.2025.11.015_bib11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.11.015_bib12","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.11.015_bib13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1126\/science.aay3638","article-title":"A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis","volume":"371","author":"Krienke","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.11.015_bib14","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc7804","article-title":"Local delivery of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication across multiple preclinical tumor models","volume":"13","author":"Hotz","year":"2021","journal-title":"Sci. Transl Med."},{"key":"10.1016\/j.ymthe.2025.11.015_bib15","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.3390\/pharmaceutics13101675","article-title":"Lipid Nanoparticles for Organ-Specific mRNA Therapeutic Delivery","volume":"13","author":"Zak","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ymthe.2025.11.015_bib16","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnology"},{"key":"10.1016\/j.ymthe.2025.11.015_bib17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1038\/nature18300","article-title":"Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy","volume":"534","author":"Kranz","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2025.11.015_bib18","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1038\/s41565-024-01680-8","article-title":"Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells","volume":"19","author":"Lian","year":"2024","journal-title":"Nat. Nanotechnol"},{"key":"10.1016\/j.ymthe.2025.11.015_bib19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.52601\/bpr.2023.230022","article-title":"Surface engineering of lipid nanoparticles: targeted nucleic acid delivery and beyond","volume":"9","author":"Lin","year":"2023","journal-title":"Biophys. Rep."},{"key":"10.1016\/j.ymthe.2025.11.015_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abc9450","article-title":"CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy","volume":"6","author":"Rosenblum","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2025.11.015_bib21","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1161\/CIRCULATIONAHA.120.047211","article-title":"Specific Modified mRNA Translation System","volume":"142","author":"Magadum","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2025.11.015_bib22","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1161\/CIRCULATIONAHA.119.043067","article-title":"Pkm2 Regulates Cardiomyocyte Cell Cycle and Promotes Cardiac Regeneration","volume":"141","author":"Magadum","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2025.11.015_bib23","first-page":"6","article-title":"Chemotherapy Treatment Considerations in Metastatic Breast Cancer","volume":"12","author":"Hanna","year":"2021","journal-title":"J. Adv. Pract. Oncol."},{"key":"10.1016\/j.ymthe.2025.11.015_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.11.015_bib25","doi-asserted-by":"crossref","first-page":"495","DOI":"10.4240\/wjgs.v15.i4.495","article-title":"Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review","volume":"15","author":"Kumar","year":"2023","journal-title":"World J. Gastrointest. Surg."},{"key":"10.1016\/j.ymthe.2025.11.015_bib26","first-page":"1","article-title":"A review of the evolution of systemic chemotherapy in the management of colorectal cancer","volume":"14","author":"Gustavsson","year":"2015","journal-title":"Clin. Colorectal Cancer"},{"key":"10.1016\/j.ymthe.2025.11.015_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030627","article-title":"Chemotherapy Side-Effects: Not All DNA Damage Is Equal","volume":"14","author":"van den Boogaard","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.11.015_bib28","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3389\/fonc.2020.01195","article-title":"Multi-Omics Characterization of the 4T1 Murine Mammary Gland Tumor Model","volume":"10","author":"Schr\u00f6rs","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2025.11.015_bib29","doi-asserted-by":"crossref","first-page":"5665","DOI":"10.1038\/s41467-023-40841-6","article-title":"MYC Deregulation and PTEN Loss Model Tumor and Stromal Heterogeneity of Aggressive Triple-Negative Breast Cancer","volume":"14","author":"Doha","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.11.015_bib30","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1159\/000495956","article-title":"Loss of Tumor Suppressor Gene Function in Human Cancer: An Overview","volume":"51","author":"Wang","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.ymthe.2025.11.015_bib31","doi-asserted-by":"crossref","first-page":"7596","DOI":"10.1073\/pnas.1600934113","article-title":"Deletion of the gene Pip4k2c, a novel phosphatidylinositol kinase, results in hyperactivation of the immune system","volume":"113","author":"Shim","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.11.015_bib32","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13578-020-00396-1","article-title":"mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges","volume":"10","author":"Zou","year":"2020","journal-title":"Cell Biosci"},{"key":"10.1016\/j.ymthe.2025.11.015_bib33","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.9207.1","article-title":"mTOR inhibitors in cancer therapy","volume":"5","author":"Xie","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.ymthe.2025.11.015_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14740338.2013.752814","article-title":"Adverse events associated with mTOR inhibitors","volume":"12","author":"Pallet","year":"2013","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ymthe.2025.11.015_bib35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s43018-023-00704-x","article-title":"Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation","volume":"5","author":"Rogava","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.ymthe.2025.11.015_bib36","article-title":"CTLA-4 blockade in tumor models: an overview of preclinical and translational research","volume":"13","author":"Grosso","year":"2013","journal-title":"Cancer Immun."},{"key":"10.1016\/j.ymthe.2025.11.015_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14163860","article-title":"Modern Immunotherapy in the Treatment of Triple-Negative Breast Cancer","volume":"14","author":"Wesolowski","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2025.11.015_bib38","doi-asserted-by":"crossref","first-page":"101405","DOI":"10.1016\/j.tranon.2022.101405","article-title":"Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumor progression in preclinical breast and colon model with independent regulatory T cells response","volume":"20","author":"Rupp","year":"2022","journal-title":"Translational Oncol."},{"key":"10.1016\/j.ymthe.2025.11.015_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/1756284820917527","article-title":"Advances in immunotherapy for colorectal cancer: a review","volume":"13","author":"Golshani","year":"2020","journal-title":"Therap Adv. Gastroenterol."},{"key":"10.1016\/j.ymthe.2025.11.015_bib40","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/j.gastha.2023.09.007","article-title":"Colorectal Cancer Immunotherapy: State of the Art and Future Directions","volume":"2","author":"Cornista","year":"2023","journal-title":"Gastro Hep Adv."},{"key":"10.1016\/j.ymthe.2025.11.015_bib41","doi-asserted-by":"crossref","first-page":"e7181","DOI":"10.1371\/journal.pone.0007181","article-title":"miR-200 Enhances Mouse Breast Cancer Cell Colonization to Form Distant Metastases","volume":"4","author":"Dykxhoorn","year":"2009","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymthe.2025.11.015_bib42","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nbt.1618","article-title":"Therapeutic silencing of miR-10b inhibits metastasis in a mouse mammary tumor model","volume":"28","author":"Ma","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2025.11.015_bib43","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3389\/fonc.2020.01415","article-title":"Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors","volume":"10","author":"Pasculli","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2025.11.015_bib44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms14630","article-title":"Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge","volume":"8","author":"Pardi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2025.11.015_bib45","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.754436","article-title":"Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade","volume":"12","author":"Appleton","year":"2021","journal-title":"Front Immunol."},{"key":"10.1016\/j.ymthe.2025.11.015_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154015","article-title":"Activation of mitochondrial-associated apoptosis signaling pathway and inhibition of PI3K\/Akt\/mTOR signaling pathway by voacamine suppress breast cancer progression","volume":"99","author":"Zuo","year":"2022","journal-title":"Phytomedicine"},{"key":"10.1016\/j.ymthe.2025.11.015_bib47","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1158\/0008-5472.CAN-15-2946","article-title":"Autophagy Differentially Regulates Distinct Breast Cancer Stem-like Cells in Murine Models via EGFR\/Stat3 and Tgfbeta\/Smad Signaling","volume":"76","author":"Yeo","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.11.015_bib48","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/bies.201500032","article-title":"Mouse models of colorectal cancer as preclinical models","volume":"37","author":"McIntyre","year":"2015","journal-title":"Bioessays"},{"key":"10.1016\/j.ymthe.2025.11.015_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.0040180","article-title":"High guanine and cytosine content increases mRNA levels in mammalian cells","volume":"4","author":"Kudla","year":"2006","journal-title":"Plos Biol."},{"key":"10.1016\/j.ymthe.2025.11.015_bib50","doi-asserted-by":"crossref","first-page":"W526","DOI":"10.1093\/nar\/gki376","article-title":"JCat: a novel tool to adapt codon usage of a target gene to its potential expression host","volume":"33","author":"Grote","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymthe.2025.11.015_bib51","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic Immunity Is Required for Effective Cancer Immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ymthe.2025.11.015_bib52","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ymthe.2025.11.015_bib53","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/gt.2010.157","article-title":"Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver","volume":"18","author":"Qiao","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2025.11.015_bib54","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/s41563-024-01961-6","article-title":"Tumour-derived small extracellular vesicles act as a barrier to therapeutic nanoparticle delivery","volume":"23","author":"Gong","year":"2024","journal-title":"Nat. Mater."},{"key":"10.1016\/j.ymthe.2025.11.015_bib55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymthe.2025.11.015_bib56","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/CIRCULATIONAHA.112.100560","article-title":"Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues","volume":"126","author":"Khouri","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2025.11.015_bib57","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1002\/cncr.30547","article-title":"Treatment-associated toxicities reported by patients with early-stage invasive breast cancer","volume":"123","author":"Friese","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.ymthe.2025.11.015_bib58","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2025.11.015_bib59","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s12935-021-02407-8","article-title":"Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier","volume":"22","author":"Vafaei","year":"2022","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.ymthe.2025.11.015_bib60","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ymthe.2025.11.015_bib61","article-title":"Current Advancements in Addressing Key Challenges of Therapeutic Antibody Design, Manufacture, and Formulation","volume":"8","author":"Sifniotis","year":"2019","journal-title":"Antibodies (Basel)"},{"key":"10.1016\/j.ymthe.2025.11.015_bib62","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/sj.cgt.7700176","article-title":"Interleukin-12 gene therapy of a weakly immunogenic mouse mammary carcinoma results in reduction of spontaneous lung metastases via a T-cell-independent mechanism","volume":"7","author":"Rakhmilevich","year":"2000","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2025.11.015_bib63","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2025.11.015_bib64","doi-asserted-by":"crossref","first-page":"11774","DOI":"10.1073\/pnas.1410626111","article-title":"Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells","volume":"111","author":"Kim","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.11.015_bib65","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/s41591-020-0892-6","article-title":"Systemic dysfunction and plasticity of the immune macroenvironment in cancer models","volume":"26","author":"Allen","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2025.11.015_bib66","doi-asserted-by":"crossref","first-page":"22699","DOI":"10.1073\/pnas.1821218116","article-title":"Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies","volume":"116","author":"Wei","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2025.11.015_bib67","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s00262-022-03170-z","article-title":"Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy","volume":"71","author":"Sato","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ymthe.2025.11.015_bib68","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1186\/s40425-019-0794-7","article-title":"Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery","volume":"7","author":"Taylor","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2025.11.015_bib69","doi-asserted-by":"crossref","first-page":"7276","DOI":"10.1158\/0008-5472.CAN-05-2128","article-title":"Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity","volume":"66","author":"Kocak","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2025.11.015_bib70","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/978-1-0716-0668-1_21","article-title":"In Vitro Synthesis of Modified RNA for Cardiac Gene Therapy","volume":"2158","author":"Sultana","year":"2021","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2025.11.015_bib71","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm871","article-title":"Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells","volume":"9","author":"De Palma","year":"2003","journal-title":"Nat. Med."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625009542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001625009542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:22:54Z","timestamp":1773933774000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001625009542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":71,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1525001625009542"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.11.015","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A tumor-selective mRNA system enables precision cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2025.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}